Patent Yard Sign in
Canadian application, no grantCanada

Anti-irritant compositions containing a cyclic 2'-deoxy-nucleotide

CA 2336362 A1 · Owner: Goyarts, Earl C. · Inventors: Muizzuddin, Neelam; Goyarts, Earl C.; Mammone, Thomas

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

The present invention relates to cosmetic or pharmaceutical topical compositions containing at least one cyclic nucleotide having its 2' hydroxyl group replaced by a hydrogen atom for inhibiting phosphodiesterase activity. The phosphodiesterase inhibitor is in combination with a magnesium buffer and a cosmetically or pharmaceutically acceptable carrier. The invention also includes methods for treating or preventing inflammation or irritation such as is common in the skin disease, atopic dermatitis which is known to be related , to the uncontrolled activity of phosphodiesterase.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Filed February 15, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended February 15, 2020.
  • A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 15, 2022.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledFebruary 15, 2000
GrantedNo grant recorded
Term endedFebruary 15, 2020
Patent numberCA 2336362 A1
Classification (IPC)A61K31/70 +2 more

Timeline

Timeline From CIPO dates

2001200320052007200920112013201520172019Application filedFeb 15, 2000Term endedFeb 15, 2020

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.